Subscribe
shutterstock-135807488-web
Photo: lucarista / Shutterstock.com
14 April 2014Europe

UK High Court strikes down Herceptin patents

The UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) after a challenge by generic drug maker Hospira.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
UK High Court upholds Alcon glaucoma patent
27 April 2021   The UK High Court has refused to invalidate an Alcon glaucoma treatment patent in a judgment handed down on Friday, April 23.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Generics
UK High Court upholds Alcon glaucoma patent
27 April 2021   The UK High Court has refused to invalidate an Alcon glaucoma treatment patent in a judgment handed down on Friday, April 23.

More on this story

Generics
UK High Court upholds Alcon glaucoma patent
27 April 2021   The UK High Court has refused to invalidate an Alcon glaucoma treatment patent in a judgment handed down on Friday, April 23.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court